共 28 条
[11]
Mega M.S., Cummings J.L., Fiorello T., Gornbein J., The spectrum of behavioral changes in Alzheimer's disease, Neurology, 46, 1, pp. 130-135, (1996)
[12]
Hill J.W., Futterman R., Duttagupta S., Mastey V., Lloyd J.R., Fillit H., Alzheimer's disease and related dementias increase costs of comorbidities in managed medicare, Neurology, 58, 1, pp. 62-70, (2002)
[13]
McCarten J.R., Anderson P., Kuskowski M.A., Et al., Changes in outpatient costs following screening and diagnosis of cognitive impairment, Alzheimers Dement., 6, 4 SUPPL., (2010)
[14]
Knopman D., Schneider L., Davis K., Talwalker S., Smith F., Hoover T., Gracon S., Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Neurology, 47, 1, pp. 166-177, (1996)
[15]
Geldmacher D.S., Provenzano G., McRae T., Mastey V., Ieni J.R., Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease, Journal of the American Geriatrics Society, 51, 7, pp. 937-944, (2003)
[16]
Lopez O.L., Becker J.T., Saxton J., Sweet R.A., Klunk W., DeKosky S.T., Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition, Journal of the American Geriatrics Society, 53, 1, pp. 83-87, (2005)
[17]
Feldman H.H., Pirttila T., Dartigues J.F., Everitt B., Van Baelen B., Schwalen S., Et al., Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease, Int J Geriatr Psychiatry., 24, 5, pp. 479-488, (2009)
[18]
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial, Lancet, 363, 9427, pp. 2105-2115, (2004)
[19]
Rascati K.L., Smith M.J., Neilands T., Dealing with skewed data: An example using asthma-related costs of medicaid clients, Clinical Therapeutics, 23, 3, pp. 481-498, (2001)
[20]
Efron B., Tibshirani R.J., An Introduction to the Bootstrap, (1993)